Which should you choose? Here's what you need to know.
Tirzepatide targets two receptors (GIP + GLP-1) and has shown slightly more weight loss in trials. Semaglutide is more established with longer real-world data.
Semaglutide is the active ingredient in Ozempic and Wegovy. It's a single GLP-1 receptor agonist with years of clinical data and FDA approval for both diabetes and weight loss.
Choose Semaglutide if:
You want a well-established option with the most real-world data, or your provider is more familiar with GLP-1 dosing protocols.
Tirzepatide (Mounjaro/Zepbound) is a newer dual-action peptide hitting both GIP and GLP-1 receptors. Clinical trials showed up to 22.5% body weight reduction.
Choose Tirzepatide if:
You want the latest generation with potentially greater weight loss, or you haven't responded well to GLP-1-only options.
Once you've decided which peptide fits your needs, here's how they compare on price and vendor options.
Our top-rated vendor for each, based on trust scores, purity testing, and price.
We re-check vendor prices continuously and score vendors on Finnrick blind-test results — samples bought anonymously and sent to a lab, not vendor claims. No vendor can pay to rank higher. See our full methodology.